Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200-Day Moving Average – What’s Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.53 and traded as high as $4.59. Cumberland Pharmaceuticals shares last traded at $4.40, with a volume of 118,912 shares.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th.

Cumberland Pharmaceuticals Price Performance

The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $60.48 million, a price-to-earnings ratio of -5.62 and a beta of -0.18. The business’s 50-day moving average is $4.44 and its 200-day moving average is $2.56.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The firm had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Institutional Trading of Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP lifted its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,649 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent reporting period. Institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.